The HIV Prevention Trials Network 052 study (HPTN 052) was a clinical trial designed to determine whether early treatment for HIV infection prevented transmission of the virus in couples where one partner was infected with HIV and the other was not, referred to as HIV serodiscordant or serodifferent couples. The study enrolled 1,763 couples at 13 sites in 9 countries in Asia, Africa, and the Americas. HPTN 052 demonstrated a minimum of 96% reduction of HIV in heterosexual couples ascribed to antiretroviral treatment; early treatment of HIV significantly reduced other infections in the HIV-infected subjects. This study, in conjunction with similar research, led to significant changes in international HIV treatment guidelines and the concept of treatment as prevention (TasP). This article provides the scientific background and history of how HPTN 052 came into being, the challenges it faced, and the ultimate impact it had on the fields of HIV treatment and prevention.

中文翻译：

---

预防HIV传播和HPTN 052研究。

HIV预防试验网络052研究（HPTN 052）是一项临床试验，旨在确定早期的HIV感染治疗是否能阻止一对伴侣感染了艾滋病毒而另一伴侣没有感染艾滋病毒的夫妇传播该病毒，这被称为HIV Serodiscordant或异国情侣。该研究在亚洲，非洲和美洲的9个国家的13个地点招募了1,763对夫妇。HPTN 052证明，归因于抗逆转录病毒治疗的异性恋夫妇，HIV感染率至少降低了96％；艾滋病毒的早期治疗显着减少了艾滋病毒感染者的其他感染。这项研究与类似的研究相结合，导致了国际艾滋病毒治疗指南和预防性治疗（TasP）概念的重大变化。